Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439334 | 1.00 | CASP3 (0.49) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL13489762 | 1.00 | CASP3 (0.49) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL119497 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL1564185 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL6038102 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL118209 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL14019298 | 0.89 | POLB (0.51) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL1486287 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL1486214 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 | |
| SCHEMBL30896048 | 0.89 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100047841-A1 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2010-02-25 | — | — | US | claimed |
| WO-2008106080-A9 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | WO | claimed |
| WO-2008106080-A2 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-09-04 | — | — | WO | claimed |
| US-20170291955-A1 | BISPECIFIC HER2 ANTIBODIES | ASTRAZENECA UK LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9427479-B2 | Tubulysin derivatives | MEDIMMUNE LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-9226974-B2 | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof | E. R. SQUIBB & SONS, L.L.C. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | MEDIMMUNE LLC (US) | 2015-10-15 | — | — | US | disclosed |
| WO-2015157592-A1 | BISPECIFIC HER2 ANTIBODIES | MEDIMMUNE, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155345-A1 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | MEDIMMUNE LIMITED (GB) | 2015-10-15 | — | — | WO | disclosed |
| US-20140323690-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | E. R. SQUIBB & SONS, L.L.C. | 2014-10-30 | — | — | US | disclosed |
| US-5750767-A | REACTING PROTECTED AMINO ACID WITH FLUOROFORMAMIDINIUM SALT | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5712418-A | FLUOROFORMAMIDINIUM SALTS AS FLUORINATION AGENTS TO FORM PEPTIDES | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-01-27 | — | — | US | disclosed |
| WO-1996004297-A9 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1996-05-02 | — | — | WO | disclosed |
| WO-1996004297-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0496836-B1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RES CORP TECHNOLOGIES INC (US) | 1995-06-14 | — | — | EP | disclosed |
| US-5360928-A | Synthesis and use of amino acid fluorides as peptide coupling reagents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0496836-A4 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | — | 1993-05-05 | — | — | EP | disclosed |
| EP-0496836-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS. | RES CORP TECHNOLOGIES INC (US) | 1992-08-05 | — | — | EP | disclosed |
| WO-1991005564-A1 | SYNTHESIS AND USE OF AMINO ACID FLUORIDES AS PEPTIDE COUPLING REAGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291955-A1 | BISPECIFIC HER2 ANTIBODIES | ERBB2, EGFR, ERBB3 | CASP3 3612/4885KMT2A 1894/4885PIN1 3069/4885 |
| US-20150291657-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | CASP3 912/4885KMT2A 2974/4885PIN1 4597/4885 |
| US-20140323690-A1 | ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF | WEE1, NGLY1, CD81 | CASP3 650/4885KMT2A 2238/4885PIN1 1195/4885 |
| US-20160339114-A1 | TUBULYSIN DERIVATIVES | TEKT1, TWF2, TEK | CASP3 912/4885KMT2A 2974/4885PIN1 4597/4885 |
| US-20100047841-A1 | SYNTHESIS OF DESACETOXYTUBULYSIN H AND ANALOGS THEREOF | XDH, XPA, TPX2 | CASP3 690/4885KMT2A 2105/4885PIN1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.